Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...
Hosted on MSN2d
Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% SurgeShares of Dogwood Therapeutics Inc. rose over 18% in premarket trading Friday, following a jaw-dropping 370% surge in the ...
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...
SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or ...
Shares of biotech Summit Therapeutics ( SMMT 9.31%) skyrocketed 583.7% in 2024, according to data from S&P Global Market ...
Press Release ImmunoMet Therapeutics, Inc., ("ImmunoMet", or the "Company"), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today provided a data ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.
Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...
Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback